Why I'm Considering Leaning Heavily Into Pfizer
High-yield dividend stocks have long been a cornerstone of wealth-building strategies for savvy investors. Typically offering yields above 3%, these companies have consistently outperformed the S 500 over extended time frames when dividends are diligently reinvested. This outperformance stems from the powerful combination of accelerated compounding and the tendency for high-yield stocks to be temporarily undervalued.
Pharmaceutical-powerhouse (NYSE: PFE) has recently emerged as an intriguing candidate in the high-yield category. The drugmaker's stock price has taken a significant hit, tumbling over 30% in the past 36 months. This substantial decline has pushed its dividend yield to an attractive 5.73% at current levels, well above its historical average of approximately 3.3%.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Aktie
Die Community zeigt eine Präferenz für Buy-Einschätzungen bei Pfizer Inc..
Das Kursziel von 29 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 20% gegenüber 23.14 €.
